

Best time to assess complete clinical response after chemotherapy for squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled trial

Lancet Oncology, The

18, 347-356

DOI: [10.1016/s1470-2045\(17\)30071-2](https://doi.org/10.1016/s1470-2045(17)30071-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anal cancer: leading the way. <i>Lancet Oncology</i> , The, 2017, 18, 276-277.	10.7	2
2	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 221-230.	7.4	23
4	Randomized Clinical Trials in Localized Anal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 705-718.	1.5	5
5	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) â€” Anal Cancer. <i>Colorectal Disease</i> , 2017, 19, 82-97.	1.4	45
6	Pharmacotherapy of Anal Cancer. <i>Drugs</i> , 2017, 77, 1519-1530.	10.9	6
7	Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. <i>Lancet Oncology</i> , The, 2017, 18, 1348-1359.	10.7	51
8	Surgery Is an Effective Option after Failure of Chemoradiation in Cancers of the Anal Canal and Anal Margin. <i>Oncology</i> , 2017, 93, 183-190.	1.9	11
9	Gastrointestinal Cancers: Timing Is Everything. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1051-1058.	0.8	0
10	Surveillance of anal carcinoma after radiochemotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 639-647.	2.0	2
15	Anal squamous cell carcinoma â€” State of the art management and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 65, 11-21.	7.7	37
16	Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 52-56.	4.4	9
17	Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 179-186.	1.3	18
18	HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. <i>BMC Gastroenterology</i> , 2018, 18, 30.	2.0	10
19	Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt. <i>Medical Oncology</i> , 2018, 35, 83.	2.5	1
21	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	4.9	476
22	Analysis of outcomes achieved with squamous cell carcinomas of the anus in a single university hospital over the last two decades: Clinical response rate, relapse and survival of 190 patients. <i>Journal of Surgical Oncology</i> , 2018, 117, 269-274.	1.7	0
23	Phase Iâ€”III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 222-228.	0.6	34
24	Squamous cell carcinoma of the rectum: Practice trends and patient survival. <i>Cancer Medicine</i> , 2018, 7, 6093-6103.	2.8	9

#	ARTICLE	IF	CITATIONS
25	Radiation Therapy for Anal Squamous Cell Carcinoma: A Retrospective Multicenter Study. <i>Anticancer Research</i> , 2018, 38, 6931-6938.	1.1	2
27	Experimental and investigational drugs for the treatment of anal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 941-950.	4.1	4
28	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. <i>British Journal of Cancer</i> , 2018, 119, 389-407.	6.4	92
29	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 852-871.	4.9	104
30	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. <i>Radiation Oncology</i> , 2018, 13, 83.	2.7	23
35	A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. <i>Clinical Colorectal Cancer</i> , 2019, 18, 301-306.	2.3	7
36	Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 591-605.	0.8	5
37	Pathologic response after modern radiotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S124-S134.	2.8	9
38	The Management and Prevention of Anal Squamous Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 216-225.	3.8	18
39	Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 136, 21-28.	0.6	20
40	Early versus late salvage abdominoperineal resection for anal squamous cell carcinoma: Is there a difference in survival?. <i>Journal of Surgical Oncology</i> , 2019, 120, 287-293.	1.7	4
41	Anal cancer chemoradiotherapy outcome prediction using ¹⁸ F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. <i>British Journal of Radiology</i> , 2019, 92, 20181006.	2.2	23
42	A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer. <i>Colorectal Disease</i> , 2019, 21, 632-650.	1.4	11
43	How I treat anal squamous cell carcinoma. <i>ESMO Open</i> , 2019, 4, e000711.	4.5	4
44	Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think!. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 802-808.	1.3	91
45	Anal Cancer. , 2020, , 87-98.		0
46	Microscopic intramural extension of rectal cancer after neoadjuvant chemoradiation: A meta-analysis based on individual patient data. <i>Radiotherapy and Oncology</i> , 2020, 144, 37-45.	0.6	4
47	SABR-BRIDGE: Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-Stage Lung Cancer or Oligomets During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020, 10, 580189.	2.8	19

#	ARTICLE	IF	CITATIONS
48	Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094094.	3.2	7
49	Association of Time Between Radiation and Salvage APR and Margin Status in Patients With Anal Cancer Treated With Concurrent Chemoradiation. American Surgeon, 2020, 86, 703-714.	0.8	4
50	Treatment compliance in early-stage anal cancer. Annals of Oncology, 2020, 31, 1282-1284.	1.2	2
51	Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 319-324.	1.3	3
52	Identification of Cancer-Associated Circulating Cells in Anal Cancer Patients. Cancers, 2020, 12, 2229.	3.7	6
53	High-Resolution Anoscopy Surveillance After Anal Squamous Cell Carcinoma: High-Grade Squamous Intraepithelial Lesion Detection and Treatment May Influence Local Recurrence. Diseases of the Colon and Rectum, 2020, 63, 1363-1371.	1.3	11
54	A Prospective Study of Diffusion-weighted Magnetic Resonance Imaging as an Early Prognostic Biomarker in Chemoradiotherapy in Squamous Cell Carcinomas of the Anus. Clinical Oncology, 2020, 32, 874-883.	1.4	4
55	RADIANCE â€“ Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clinical and Translational Radiation Oncology, 2020, 23, 43-49.	1.7	16
56	Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC). Frontiers in Oncology, 2020, 10, 505.	2.8	21
57	Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma: Use, Risk Factors, and Outcomes in a Canadian Population. Diseases of the Colon and Rectum, 2020, 63, 748-757.	1.3	6
58	A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape. Expert Review of Gastroenterology and Hepatology, 2020, 14, 665-680.	3.0	6
59	Management of anal cancer patients â€“ a pattern of care analysis in German-speaking countries. Radiation Oncology, 2020, 15, 122.	2.7	5
63	Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990â€“2014). British Journal of Cancer, 2020, 122, 749-758.	6.4	7
65	Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer. Updates in Surgery, 2021, 73, 7-21.	2.0	7
67	Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study. Scandinavian Journal of Gastroenterology, 2021, 56, 432-436.	1.5	5
68	S3-Leitlinie Analkarzinom. Coloproctology, 2021, 43, 1-2.	0.3	1
70	Evolution of the Role of Radiotherapy for Anal Cancer. Cancers, 2021, 13, 1208.	3.7	13
71	Anal Cancer. Deutsches Ärzteblatt International, 2021, 118, .	0.9	1

#	ARTICLE	IF	CITATIONS
72	Emerging and Experimental Agents for Anal Cancer: What is New?. Journal of Experimental Pharmacology, 2021, Volume 13, 433-440.	3.2	7
75	Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences. Digestive and Liver Disease, 2021, 53, 1492-1498.	0.9	5
76	Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations. ESMO Open, 2021, 6, 100180.	4.5	21
77	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nature Reviews Clinical Oncology, 2021, 18, 805-816.	27.6	93
78	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. Clinical Colorectal Cancer, 2021, 20, 279-287.	2.3	6
79	Practice of radiation therapy for anal cancer in Austria – a survey on behalf of the Austrian radiation oncology society gastrointestinal tumor group (Ä–GRO-GIT). Strahlentherapie Und Onkologie, 2021, 197, 953-961.	2.0	4
80	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 2021, 32, 1087-1100.	1.2	100
81	Chemoradiation for Anal Cancer: Clinical Outcomes and Strategies to Optimize the Therapeutic Ratio According to HPV Status. Seminars in Radiation Oncology, 2021, 31, 349-360.	2.2	3
82	A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes. Journal of Cancer, 2021, 12, 7018-7025.	2.5	3
84	Radiation Therapy in Anal Cancer. , 2018, , 1-23.		0
85	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
87	Treatment of Localized Anal Cancer: Chemoradiotherapy. , 2019, , 47-70.		0
88	Management of Local-Regional Anal Cancer Recurrence. , 2019, , 85-93.		0
89	Anal Cancer. , 2020, , 27-48.		0
90	Current treatment and future directions in the management of anal cancer. Ca-A Cancer Journal for Clinicians, 2022, 72, 183-195.	329.8	12
92	Do We Have Enough Evidence to Propose a Preferred Total Neoadjuvant Therapy Sequence for Patients With Locally Advanced Rectal Cancer?. JAMA Oncology, 2022, , .	7.1	1
93	Anal cancer in Sweden 2015–2019. Implementation of guidelines, structural changes, national registry and early results. Acta Oncologica, 2022, 61, 575-582.	1.8	2
94	Anal cancer. , 2021, , 160-167.		0

#	ARTICLE	IF	CITATIONS
95	A Pattern of Care Report on the Management of Patients with Squamous Cell Carcinoma of the Anus – A Study by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Tumors Study Group. <i>Medicina (Lithuania)</i> , 2021, 57, 1342.	2.0	0
96	Anal cancer in older adults: A Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2022, 13, 914-923.	1.0	2
98	The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1073-1085.	3.0	4
99	Anal Cancer: Emerging Standards in a Rare Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 2774-2788.	1.6	13
100	Leukocyte subtyping predicts for treatment failure and poor survival in anal squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	2.6	0
101	ECOG-ACRIN Guideline for Contouring and Treatment of Early Stage Anal Cancer Using IMRT/IGRT. <i>Practical Radiation Oncology</i> , 2022, 12, 335-347.	2.1	10
102	Long-Term Disease Control After Locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
103	A pilot study investigating the role of ^{18}F -FDG-PET in the early identification of chemoradiotherapy response in anal cancer. <i>Journal of Medical Radiation Sciences</i> , 2022, 69, 439-447.	1.5	4
104	Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study. <i>Diagnostic and Prognostic Research</i> , 2022, 6, .	1.8	3
105	Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies. <i>Biomedicines</i> , 2022, 10, 2029.	3.2	3
106	Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
108	The first comprehensive genomic characterization of rectal squamous cell carcinoma. <i>Journal of Gastroenterology</i> , 2023, 58, 125-134.	5.1	5
109	Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
112	Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2023, 35, 44-57.	2.2	1
113	Anal Cancer: The Past, Present and Future. <i>Current Oncology</i> , 2023, 30, 3232-3250.	2.2	6
114	Treatment Outcomes of Chemoradiotherapy for Anal Canal Squamous Cell Carcinoma in Japan. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2023, 76, 347-352.	0.0	0
115	Brazilian Society of Surgical Oncology: Guidelines for the management of anal canal cancer. <i>Journal of Surgical Oncology</i> , 0, , .	1.7	0
117	Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903). <i>International Journal of Clinical Oncology</i> , 0, , .	2.2	0

#	ARTICLE	IF	CITATIONS
118	Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
119	Neoadjuvant immunotherapy in microsatellite unstable colorectal cancer: Are we in the era of nonoperative management?. <i>Journal of Surgical Oncology</i> , 2023, 127, 1296-1299.	1.7	0
120	Staging and Treatment. II-3. Definitive Chemoradiotherapy for Anal Cancer. , 2023, , 309-314.		0
121	Diffusion-weighted imaging complements T2-weighted MRI for tumour response assessment in squamous anal carcinoma. <i>European Radiology</i> , 0, , .	4.5	1
122	Anal cancer MRI: DWI assists response assessment for squamous cell carcinoma, but achieving widespread high-quality scans remains challenging. <i>European Radiology</i> , 0, , .	4.5	0
123	Chemoradiotherapy efficacy in squamous cell rectal cancer: a propensity score matched analysis. <i>Siberian Journal of Oncology</i> , 2023, 22, 14-21.	0.3	0
124	Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma. <i>Clinical and Translational Oncology</i> , 2024, 26, 739-746.	2.4	0
125	Prognostic significance of delayed complete metabolic response on PET/CT after primary chemoradiation treatment of cervical cancer. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2023-004703.	2.5	0
126	Prognostic impact of post-treatment FDG PET/CT in anal canal cancer: A prospective study. <i>Radiotherapy and Oncology</i> , 2023, 188, 109905.	0.6	0
127	A retrospective analysis of concurrent chemoradiation for squamous cell carcinoma of the anus in Johannesburg. <i>South African Journal of Oncology</i> , 0, 7, .	0.1	0
128	IAP inhibitor plus chemoradiotherapy for the treatment of bulky anal canal carcinoma. , 2023, 40, .		0
132	Sub-lobar resections for peripheral non-small cell lung cancer measuring 2cm: Insights from recent clinical trials. <i>Radiotherapy and Oncology</i> , 2024, 192, 110094.	0.6	0